Dow Jones 30 Stocks SEC Filings — June 10, 2026

10-06-2026

Purebase Corporation announced the appointment of Dr. Amy T. Clemens as Chief Financial Officer, effective June 5, 2026. Dr. Clemens previously served as interim CFO for two years during the company's inception and returns from the defense industry. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons or quantitative trends are available.

• · Dr. Clemens previously served as interim CFO for 2 years during Purebase's inception before returning to the defense industry.
• · The appointment is effective June 5, 2026.
• · The company describes itself as a 'highly diversified mineral resource company' and a 'diversified resource company' that acquires, develops and markets high-value minerals and agricultural products.

10-06-2026

Vanguard Green Investment Ltd reported zero revenue for the three and nine months ended April 30, 2026, with net losses widening to $19,062 (Q3) and $66,191 (nine months) compared to $11,146 and $40,251 in the prior-year periods. The company's accumulated deficit increased to $2,627,012 and total stockholders' deficit deepened to $790,769, while cash and cash equivalents fell to just $55 from $93 at July 31, 2025. The company continues to rely on director loans ($57,749 in financing during the nine months) to fund operations, with no revenue-generating activities reported.

• · Revenue remained zero for all periods reported, with no cost of revenue or gross profit.
• · Other income was $0 for the three and nine months ended April 30, 2026, compared to $832 and $875 in the prior-year periods.
• · Selling and marketing expenses were $0 for all periods.
• · Income tax provision was $0 for all periods.
• · No foreign currency translation loss was recorded.
• · Net loss per share (basic and diluted) was $(0.0003) for Q3 2026 vs $(0.0002) for Q3 2025, and $(0.0011) vs $(0.0007) for the nine-month periods.
• · Weighted average shares outstanding remained constant at 59,434,838.
• · Property, plant and equipment was fully depreciated and impaired to $0 as of both balance sheet dates.
• · Patent and trademark intangible asset was $0.
• · Total assets increased slightly from $15,258 to $16,555, driven by a rise in prepayments.
• · Total liabilities increased from $739,836 to $807,324, primarily due to higher director and third-party loans.
• · The company had no preferred stock issued or outstanding.
• · Cash used in operating activities increased to $57,787 from $43,981 (nine months).
• · The company's only source of cash from financing was director loans.
• · The company's cash balance at period end was only $55, indicating severe liquidity constraints.

10-06-2026

Elevance Health reaffirmed its full-year 2026 guidance, expecting at least $19.85 per diluted share in reported shareholders' earnings, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the company maintains its outlook for adjusted shareholders' earnings of at least $26.75 per diluted share, and reaffirmed the full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. No period-over-period comparisons or new financial results were provided in this filing.

10-06-2026

General Fusion Inc. was named the World's Top GreenTech Company of 2026 by TIME, highlighting its progress toward commercial fusion energy. The recognition comes as General Fusion advances its proposed business combination with Spring Valley Acquisition Corp. III (NASDAQ: SVAC) to become a publicly listed company. The company's LM26 fusion demonstration machine is now in operation, aiming to achieve key technical milestones, but the transaction remains subject to regulatory approvals and shareholder votes, with no guaranteed completion timeline.

• · General Fusion was established in 2002 and is headquartered in Vancouver, Canada.
• · LM26 mechanically compresses plasma with a lithium liner at 50% commercial-scale diameter.
• · LM26 aims to achieve plasma heating to 1 keV (10 million degrees Celsius), then 10 keV (100 million degrees Celsius), and ultimately the Lawson criterion for net fusion energy.
• · Spring Valley I completed a business combination with NuScale Power Corporation (SMR technology).
• · Spring Valley II completed a business combination with Eagle Nuclear Energy Corp. (uranium deposit rights).
• · The proposed business combination involves SVAC continuing from Cayman Islands to British Columbia, amalgamation of NewCo with General Fusion, and name change to 'General Fusion Group Ltd.'
• · The filing includes forward-looking statements and risk factors related to the business combination, including potential failure to complete, regulatory approvals, and LM26 program risks.

10-06-2026

Silver Bull Resources, Inc. announced on June 1, 2026 that its arbitration case against Mexico has been dismissed in its entirety by an ICSID tribunal, which concluded it lacked jurisdiction and/or the claim was time-barred. The company has been ordered to pay approximately US$998,000 of Mexico's legal costs. Silver Bull is assessing grounds for annulment (with 120 days to register) and evaluating strategic options, including seeking resolution of the ongoing blockade of its Sierra Mojada property or identifying other exploration projects.

• · The arbitration hearing was held in Washington, D.C. in October 2025.
• · Silver Bull submitted its post-hearing brief on November 21, 2025 and its costs on December 5, 2025.
• · The final award was rendered on May 29, 2026.
• · The company has 120 days from the ruling to register for annulment, and the proceeding would take approximately 18 to 36 months.
• · The arbitration arose from Mexico's expropriation and other treatment related to the blockade of the Sierra Mojada property.

10-06-2026

Allegiant Travel Company announced a private offering of $650 million aggregate principal amount of 7.125% Senior Secured Notes due 2031 at an offering price of 99.479% of par. The offering size was increased by $150 million from the previously announced $500 million. The notes are expected to be issued on June 24, 2026, subject to customary closing conditions.

• · The offering size was increased by $150M from the initially announced $500M to $650M.
• · The Notes are being offered at 99.479% of principal amount.
• · The offering is private, not registered under the Securities Act, relying on Rule 144A and Regulation S.
• · The Notes are expected to be issued on June 24, 2026.

10-06-2026

American Ventures Acquisition Corp. I filed an S-1 registration statement on June 9, 2026, for an initial public offering (IPO) as a blank check company. The filing details redemption rights for public stockholders upon completion of a business combination, with an anticipated trust account value of $5.00 per public share. However, the filing also includes a limitation that stockholders holding 15% or more of shares sold in the offering are restricted from redeeming more than that threshold without prior consent, which could reduce liquidity for large holders.

• · The filing is under SEC file number 333-296656.
• · The company is incorporated in Florida and classified under SIC 6770 (Blank Checks).
• · Redemption rights can be exercised via stockholder vote or tender offer, with tender offers required to remain open for at least 20 business days.
• · If stockholder approval is required, a majority of votes entitled to be cast is needed for approval.
• · The company may raise additional funds through equity-linked securities or debt to meet minimum cash requirements.
• · The limitation on redemption for holders of 15% or more of shares is designed to prevent large stockholders from blocking business combinations.

10-06-2026

RemSleep Holdings Inc. (RMSL) reported no revenue for Q1 2026, consistent with the prior-year period. Net loss widened significantly to $289,924 from $85,488 in Q1 2025, driven by a 76% increase in operating expenses to $231,348. Cash fell 59% to $87,953 from $214,514 at year-end 2025, and stockholders' equity turned negative at ($122,551) versus $32,062 at December 31, 2025, reflecting ongoing cash burn and operating losses.

• · Inventory increased 52% to $70,356 from $46,304 at year-end 2025.
• · Accounts payable rose 51% to $173,357 from $114,761.
• · The company issued 35,419,997 shares of common stock for note payable principal and accrued interest, valued at $135,311.
• · Derivative liability increased to $78,038 from $63,920 at December 31, 2025.
• · Accumulated deficit grew to $18,580,980 from $18,291,056.

10-06-2026

VolitionRX Ltd (VNRX) priced a $4.6 million public offering on June 7, 2026, issuing 2,960,000 shares and warrants for up to 1,480,000 shares at a combined price of $1.55 per share. The offering includes participation from new and existing investors, with potential additional gross proceeds of up to $2.3 million from warrant exercises, though no assurance of exercise is given. The offering is expected to close on June 9, 2026.

• · The offering is being conducted under an effective shelf registration statement on Form S-3 (File No. 333-283088), filed with the SEC on November 8, 2024, and declared effective on April 18, 2025.
• · Each warrant has an exercise price of $1.55 per share, is exercisable immediately upon issuance, and expires five years after issuance.
• · Maxim Group LLC is the sole placement agent, and the offering is expected to close on June 9, 2026.
• · The company cautions that no assurance can be given that any warrants will be exercised.
• · VolitionRX is a multinational epigenetics company focused on developing blood tests for cancer and NETosis-related diseases like sepsis.

10-06-2026

Vitesse Energy, Inc. held its Annual Meeting on June 5, 2026, where stockholders elected eight directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. All director nominees were elected, though Joseph S. Steinberg received the lowest support with over 3 million votes against, while Gary D. Reaves received the highest support. The ratification of Deloitte & Touche passed with overwhelming approval, with over 29 million votes in favor.

• · Total shares outstanding and voting power not disclosed, but broker non-votes were 7,029,180 for each director election.
• · Proposal 2 (auditor ratification) had no broker non-votes, with 29,213,741 votes for, 821,700 against, and 167,487 abstained.
• · Joseph S. Steinberg received the most votes against (3,062,853) among director nominees, while Gary D. Reaves received the most votes for (22,032,901).

10-06-2026

Enliven Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation on June 9, 2026, increasing total authorized shares to 210,000,000, consisting of 200,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock, each with a par value of $0.001. The amendment was duly adopted by the Board of Directors and stockholders.

• · Original certificate of incorporation filed under the name IMARA Inc. on January 26, 2016.
• · Amendment effective June 9, 2026.
• · Par value for both Common and Preferred Stock is $0.001 per share.

10-06-2026

Teamshares CEO Michael Brown discussed the company's business model and growth plans on a podcast, highlighting its strategy as a tech-enabled acquirer of small to mid-size enterprises with a focus on employee ownership. The company reported $19 million in proforma adjusted EBITDA for 2025 and forecasts growth to $60 million in 2026 and $100 million by 2027, driven by a massive generational transition among small business owners. However, the filing contains forward-looking statements with significant risks, including potential failure to complete the business combination with Live Oak Acquisition Corp. V and the inability to achieve projected financial targets.

• · Teamshares acquires companies with EBITDA between $0.5M and $5M from retiring owners.
• · The company operates as a consolidated operating company, not an investment fund.
• · Over 75,000 businesses are actively for sale in Teamshares' software annually.
• · The business combination agreement was dated November 14, 2025.
• · Live Oak's public shareholders may redeem shares, posing a risk to the deal.
• · The filing includes a transcript generated by automated tools with possible errors.

10-06-2026

Bread Financial Holdings, Inc. filed an 8-K on June 10, 2026, containing a press release (Exhibit 99.1) with a performance update for the period ended May 31, 2026. The filing is a Regulation FD disclosure; the press release was not filed for Section 18 Exchange Act purposes. The actual performance figures are not included in this 8-K text, only the notice of the press release.

• · Filing type is 8-K under items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• · The performance update press release is attached as Exhibit 99.1 but its content is not included in this filing text.
• · The press release is furnished, not filed, for purposes of Section 18 liability.
• · Company headquarters located at 3095 Loyalty Circle, Columbus, Ohio 43219.

10-06-2026

Rafael Holdings announced the completion of the last patient's final 96-week visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C. Topline data from the main cohort is expected in H2 2026, and the company has completed a pre-NDA meeting with the FDA, with an NDA submission anticipated in H2 2026. The FDA also acknowledged that the company's US Expanded Access Program can proceed.

• · The TransportNPC™ study is described as the most comprehensive, controlled pivotal study for NPC in terms of patient size, global footprint, duration, and clinical outcomes.
• · No serious adverse events considered related to the study drug were reported in the pediatric sub-study.
• · The company expects to transition into a commercial-stage biotechnology company upon NDA submission.
• · Data from the pediatric sub-study was presented at WORLDSymposium 2026.

10-06-2026

CervoMed Inc. announced a private placement financing with expected gross proceeds of approximately $10.5 million, extending cash runway into Q2 2027. The company plans to focus on strategic partnering to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). However, the Phase 3 trial initiation is contingent on securing a partnership and/or additional financing, and the company faces risks from potential dilution and reliance on future funding.

• · The private placement includes 3,360,377 Units, each consisting of common stock or pre-funded warrant, Series B warrant, and Series C warrant.
• · Series B warrants expire June 11, 2031; Series C warrants expire June 11, 2027; pre-funded warrants have no expiration.
• · The company has alignment with FDA (Nov 2025), UK MHRA, and EMA (Jan 2026) on potential registration path for neflamapimod in DLB.
• · Phase 3 dosing regimen is 50mg TID of stable crystal form; initial Phase 3 clinical drug batch manufactured and released.
• · A 39-week chronic toxicity study increased neflamapimod's no adverse effect level threefold and widened safety margin to ~30-fold above clinically active exposures.
• · Phase 2a trial in nfvPPA fully enrolled; interim biomarker data expected early Q4 2026, 24-week clinical data in Q1 2027.
• · EXPERTS-ALS Phase 2a trial expected to dose first patient in Q4 2026.
• · Insiders including Joshua S. Boger, John J. Alam, and Sylvie Grégoire participated in the financing.

10-06-2026

Virgin Galactic redeemed $30.5M of its 9.80% First Lien Notes due 2028 by issuing 6.7M shares of common stock on June 10, 2026, as part of a broader capital management strategy to improve liquidity and reduce cash interest obligations. After the redemption, approximately $172M in aggregate principal amount of First Lien Notes remains outstanding, with no principal payment due until March 31, 2028. The company is preparing for commercial operations in Q4 2026.

• · The redemption was executed using a volume-weighted average price over a five-day observation period as specified in the indenture.
• · The shares were issued in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
• · No principal payment is due on the remaining First Lien Notes until March 31, 2028.

10-06-2026

Getty Images Holdings, Inc. disclosed in a Form 425 filing that on June 9, 2026, a New York State Supreme Court issued a decision granting plaintiffs' motion for summary judgment in the Funicular Funds LP lawsuit. The court conditionally granted summary judgment as to certain warrants (subject to plaintiffs providing authorization letters by August 10, 2026), and plaintiffs sought $67,811,031 plus pre-judgment interest, which the company had already reserved against in its balance sheet reported in the May 11, 2026 Form 10-Q. However, the final judgment amount remains uncertain pending the court’s direction and potential appeals.

• · The lawsuit was originally filed on July 5, 2024 in New York State Supreme Court, New York County; Index No. 653410/2024.
• · The consolidated action generally alleges breaches of warrant agreements dated August 4, 2020.
• · Plaintiffs were given until August 10, 2026 to provide authorization letters for certain remaining warrants, after which the court will direct entry of judgment.
• · The company reserved the full $67,811,031 in its Condensed Consolidated Balance Sheet as of the May 11, 2026 Form 10-Q filing.
• · The company continues to caution that actual results could differ materially due to risks including AI-related legal/ethical issues, cybersecurity, and foreign currency fluctuations.

10-06-2026

M2i Global, Inc. received a termination notice from Volato Group, Inc. regarding their merger agreement dated July 28, 2025. M2i disputes the termination, rejects it as without merit, and intends to vigorously enforce its contractual rights, including seeking damages and equitable relief. The company cannot predict the ultimate outcome of this matter.

• · The merger agreement was dated July 28, 2025.
• · The termination notice was received on June 4, 2026.
• · Volato alleges termination is effective as of June 4, 2026, under Section 10.1 of the Merger Agreement.
• · M2i has notified Volato that it rejects the purported termination and considers the notice without merit.
• · M2i intends to pursue all available remedies, including damages and/or equitable relief.

10-06-2026

Eikon Therapeutics appointed Ma. Fatima D. Francisco as a Class I director effective June 15, 2026, with an annual retainer of $50,000 and an option to purchase 85,937 shares at $8.96 per share. No other material changes were disclosed.

• · Ms. Francisco will serve on the Compensation Committee.
• · Option vests in 48 equal monthly installments subject to continued service.
• · Ms. Francisco entered into standard indemnification agreement.
• · No arrangements or understandings with other persons regarding her selection.
• · No related person transactions required to be disclosed.

10-06-2026

Apple Hospitality REIT, Inc. announced that Elizabeth S. Perkins, Senior Vice President and Chief Financial Officer, has been appointed as the Company's principal accounting officer effective June 10, 2026, succeeding Rachel Labrecque, who passed away on June 9, 2026.

• · Ms. Perkins assumed the additional role of principal accounting officer on June 10, 2026.
• · Ms. Labrecque's passing occurred on June 9, 2026.
• · Ms. Perkins' biographical information is incorporated by reference from the Company's definitive proxy statement filed on April 2, 2026.

10-06-2026

MarketAxess Holdings Inc. held its 2026 Annual Meeting on June 10, 2026, with 90.75% of outstanding shares represented. All 12 director nominees were elected, and the say-on-pay proposal passed with strong support (30,009,045 for vs. 677,528 against). However, a stockholder proposal regarding changes to the special stockholder meeting right was overwhelmingly rejected (8,729,100 for vs. 21,935,501 against), and the ratification of PricewaterhouseCoopers as auditor passed with 30,900,982 votes in favor.

• · All 12 director nominees were elected with strong support; the lowest vote total was for William F. Cruger (29,259,117 for, 1,431,155 against).
• · The say-on-pay proposal passed with 30,009,045 votes for, 677,528 against, and 9,630 abstentions.
• · The stockholder proposal on special meeting rights was rejected with 21,935,501 against and only 8,729,100 for.
• · Broker non-votes were 1,230,593 on all director elections and the say-on-pay and stockholder proposals.

10-06-2026

Aimco held its 2026 Annual Meeting on June 10, 2026, where stockholders elected all nine director nominees, ratified Grant Thornton LLP as independent auditor for fiscal 2026, and approved executive compensation on an advisory basis. All proposals passed with strong support, though broker non-votes accounted for approximately 10.7% of outstanding shares on director elections and the say-on-pay vote.

• · Record date for the meeting was April 22, 2026.
• · Broker non-votes totaled 15,408,377 on director elections and the say-on-pay proposal, representing about 10.7% of outstanding shares.
• · Ratification of Grant Thornton LLP as independent auditor received 122,448,341 votes for, 44,640 against, and 102,692 abstentions, with no broker non-votes.
• · The advisory vote on executive compensation received 105,737,910 for, 1,060,791 against, and 388,595 abstentions.

10-06-2026

Navan reported strong Q1 FY2027 results with revenue of $220M (+40% YoY) and GBV of $3.1B (+50% YoY), while raising FY2027 revenue guidance to ~30% YoY growth. However, GAAP loss from operations widened to $18M from $16M YoY, and GAAP net loss improved significantly to $21M from $61M YoY, reflecting mixed profitability trends.

• · Subscription revenue grew 26% YoY to $18M, slower than usage revenue growth of 41%.
• · GAAP loss from operations widened to $18M from $16M YoY, a 12.5% increase.
• · Non-GAAP operating margin improved to 11% from 2% YoY.
• · GAAP net loss improved significantly to $21M from $61M YoY, a 65.6% reduction.
• · Non-GAAP net income was $22M vs. a non-GAAP net loss of $7M in the prior year.
• · Q2 FY2027 revenue guidance midpoint is $220M, implying 28% YoY growth, down from 40% in Q1.
• · FY2027 revenue guidance raised to $907-$913M (30% YoY growth at midpoint) from prior 24%.
• · FY2027 non-GAAP operating income guidance is $76-$80M, with 9% operating margin at midpoint.
• · Payment Volume grew 29% YoY to $1.3B, slower than GBV growth of 50%.
• · Navan Anywhere launched to embed booking into third-party tools like Gemini Enterprise.

10-06-2026

Veritone, Inc. announced a restructuring plan on June 1, 2026, including a workforce reduction of at least 25% of its employee count as of March 31, 2026, and cuts in third-party operating costs, aiming to reduce annual operating expenses by up to 30% compared to the trailing twelve months ended March 31, 2026. The workforce reduction began on June 10, 2026, and is expected to be substantially completed by late July 2026. The company cannot yet estimate the associated costs and charges, which will include severance, employee benefits continuation, and exit costs.

• · The restructuring plan was decided on June 1, 2026, and the workforce reduction began on June 10, 2026.
• · The workforce reduction is expected to be substantially completed by late July 2026.
• · Affected employees may receive severance based on length of service and benefits continuation, contingent on signing a separation agreement with a general release of claims.
• · The company cannot reasonably estimate the costs and charges at this time.
• · The plan aims to achieve an annualized reduction of up to 30% of operating expenses in Q3 2026.

10-06-2026

Virtu Financial, Inc. held its 2026 annual meeting on June 10, 2026, where stockholders elected three Class II directors (Aaron Simons, Joseph J. Grano, Jr., and Joanne M. Minieri) for three-year terms, approved advisory say-on-pay compensation with 98.8% support, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026. All proposals passed with strong shareholder support, though director Joseph J. Grano, Jr. received 16.7 million withheld votes (2.5% of votes cast), and Joanne M. Minieri received 26.3 million withheld votes (3.9% of votes cast), indicating some dissent.

• · Aaron Simons received 671,181,435 For votes and 776,474 Withheld (99.9% approval).
• · Joseph J. Grano, Jr. received 655,260,181 For and 16,697,728 Withheld (97.5% approval).
• · Joanne M. Minieri received 645,673,037 For and 26,284,872 Withheld (96.1% approval).
• · Advisory say-on-pay: 663,861,829 For, 8,042,616 Against, 53,464 Abstain.
• · Ratification of PwC: 679,397,651 For, 659,952 Against, 40,619 Abstain.
• · Broker non-votes were 8,140,313 on all three director and advisory proposals.

10-06-2026

vTv Therapeutics Inc. filed this DEFA14A to supplement its 2026 Proxy Statement and Proxy Card, correcting the inadvertent omission of Proposal 3—an advisory vote on named executive officer compensation. The Annual Meeting, originally convened on June 10, 2026, was adjourned without any business transacted to allow stockholders time to review the new proposal; it will resume on June 26, 2026, at 11:00 a.m. ET. There are no quantitative financial changes in this filing; the action is procedural and governance-related.

• · The deadline for voting by phone or Internet has been extended to 11:59 p.m. ET on June 24, 2026.
• · Only stockholders of record as of April 14, 2026, are entitled to vote at the annual meeting.
• · Proposal 3 requires the affirmative vote of a majority of shares present or represented by proxy (abstentions count as against).
• · Proposal 1 (election of directors) requires a plurality of votes cast, while Proposal 2 (ratification of auditor) and Proposal 3 each require a majority of voting power present/represented.
• · Broker non-votes have no effect on Proposals 1, 2, or 3, but Proposals 1 and 3 are considered non-routine, and Proposal 2 is routine.
• · If a stockholder submits a new proxy (after previously submitting one), any prior proxy is entirely revoked unless the stockholder indicates otherwise.

10-06-2026

enGene Therapeutics Inc. held its 2026 Annual General Meeting on June 9, 2026, with 56,196,302 common shares represented (83.89% of outstanding). All director nominees were elected with overwhelming support (over 99% of votes cast), and the appointment of the auditor was approved with 56,180,287 votes for and only 16,015 against. No negative or flat metrics were present.

• · The meeting was held on June 9, 2026 at 8:30 a.m. EDT.
• · Record date for voting was April 28, 2026.
• · All director nominees were elected with over 99% of votes cast in favor.
• · Auditor appointment received 56,180,287 votes for and only 16,015 against, with no broker non-votes.

10-06-2026

Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the Board size from seven to eight members. Mr. Coughlin will serve as a Class III director and Chair of the Audit Committee, effective immediately. He will receive standard non-employee director compensation, including stock option and restricted stock unit grants under the 2019 Equity Incentive Plan.

• · Mr. Coughlin was not selected pursuant to any arrangement or understanding, and no related party transactions exist under Item 404(a) of Regulation S-K.
• · The appointment is effective immediately, with Mr. Coughlin's term running until the 2028 annual meeting of stockholders.
• · Standard form indemnity agreement entered into with Mr. Coughlin, referenced from the Company's 2019 Form S-1 filing.
• · No prior period data or comparisons are provided; this is a single-event filing.

10-06-2026

M3-Brigade Acquisition V Corp. filed a DEFA14A on June 10, 2026, providing additional proxy materials regarding its proposed business combination with ReserveOne, a crypto-focused entity. The filing includes forward-looking statements and risk factors, but no specific financial figures or quantitative data are disclosed. The company urges shareholders to read the definitive proxy statement/prospectus filed on May 13, 2026.

• · Definitive proxy statement/prospectus was filed with the SEC on May 13, 2026.
• · Shareholders of record as of May 7, 2026 are entitled to vote.
• · The business combination involves a crypto-related business, with risks including volatility of cryptocurrencies and regulatory uncertainty.
• · The company's final prospectus was dated July 31, 2024 and filed on August 2, 2024.
• · Pubco's Form S-4 was filed on December 5, 2025.

10-06-2026

Arax Holdings Corp (ARAT) filed its audited 10-K for the fiscal year ended October 31, 2024, reporting a net loss of $3.56M, a significant improvement from the $6.59M net loss in the prior year. Revenue declined 32.4% to $613,636 (including $301,750 from a related party), while total assets fell 58.3% to $902,220 and stockholders' equity turned negative to ($521,414) from positive $1.81M. The company also restated its prior year financials, reducing previously reported total assets by $4.98M and eliminating a prior $18.55M impairment charge.

• · The company restated its FY2023 financials, reducing total assets by $4.98M (from $7.15M to $2.17M), eliminating a prior $18.55M impairment charge, and reclassifying $4.76M in software development costs.
• · Accounts receivable of $301,750 were recognized in FY2024, compared to $0 in the prior restated year.
• · Notes payable of $765,000 were recorded in FY2024, up from $0 in FY2023.
• · Stock-based compensation decreased 63.1% to $724,862 in FY2024 from $1,963,296 in FY2023.
• · The company reported a $169,373 impairment expense and a $103,400 loss on short-term borrowing settlement in FY2024.
• · Weighted average shares outstanding increased 88.6% to 127.8 million in FY2024 from 67.8 million in FY2023.
• · The company has limited international operations in South Africa and Switzerland (Cilandro SA) and does not hedge foreign currency exposure.
• · Total stockholders' equity turned negative to ($521,414) as of October 31, 2024, compared to positive $1.81M a year earlier.

10-06-2026

CoreWeave held its 2026 Annual Meeting on June 8, 2026, with 85.51% of combined voting power represented. Stockholders elected Michael Intrator as a Class I director, ratified Deloitte & Touche as auditor, and approved executive compensation on an advisory basis. The company will hold annual advisory votes on executive compensation going forward.

• · The record date for voting was April 15, 2026.
• · Class A common stockholders had one vote per share; Class B common stockholders had ten votes per share.
• · Proposal 4 (frequency of advisory votes on executive compensation) received 1,149,884,867 votes for 'One Year', 219,374 for 'Two Years', 690,390 for 'Three Years', and 903,910 abstentions.
• · The company will hold an annual nonbinding advisory vote on executive compensation until the next required frequency vote.

10-06-2026

Perceptive Capital Solutions Corp (PCSC) held an extraordinary general meeting on June 10, 2026, where shareholders approved an amendment to extend the deadline for consummating an initial business combination from June 13, 2026 to June 13, 2027. The extension passed overwhelmingly with 8,515,798 votes for, only 75 against, and 4,866 abstentions. However, in connection with the vote, holders of 754,008 Class A Ordinary Shares exercised their redemption rights, resulting in aggregate redemptions of approximately $8.16 million (or about $10.82 per share), reducing the trust account balance to approximately $85.17 million.

• · The extension proposal passed with 8,515,798 votes for, 75 against, and 4,866 abstentions; broker non-votes were zero.
• · The redemption price per share was approximately $10.82.
• · The adjournment proposal was not put to a vote because sufficient votes were already cast for the extension.
• · PCSC is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
• · The proposed business combination with Freenome Holdings, Inc. will be subject to a separate shareholder vote; PCSC has filed an S-4 registration statement with the SEC.

10-06-2026

Intellia Therapeutics held its 2026 Annual Meeting on June 9, 2026, where stockholders elected three Class I directors (Muna Bhanji, Brian Goff, Jesse Goodman), ratified Deloitte & Touche as independent auditor for FY2026, and approved non-binding advisory say-on-pay for named executive officers. All proposals passed, though director Jesse Goodman received the lowest support with 43.0M for vs 15.7M against.

• · Broker non-votes were 30,124,178 for director elections and say-on-pay, but zero for auditor ratification.
• · Auditor ratification received the highest support with 87,833,534 for, 779,540 against, and 249,592 abstain.
• · Say-on-pay passed with 44,806,637 for, 13,821,404 against, and 110,447 abstain.

10-06-2026

Fifth Third Bancorp completed exchange offers and consent solicitations on June 10, 2026, exchanging approximately $1.273B of existing Comerica/FTFC notes for new Fifth Third notes and cash. The exchange saw strong participation: 60.9% of the 4.000% Senior Notes due 2029 ($334.8M of $550M) and 93.8% of the 5.982% Fixed-to-Floating Rate Senior Notes due 2030 ($938.2M of $1.0B) were tendered. However, $215.2M of the 4.000% notes and $61.8M of the 5.982% notes remain outstanding and will continue under amended indentures with reduced covenants.

• · The exchange offers expired at 5:00 p.m. New York City time on June 8, 2026.
• · All accepted Existing FTFC Notes will be retired and cancelled.
• · The Proposed Amendments deleted certain covenants, including Events of Default (clauses 4 and 7), consolidation restrictions, existence, maintenance of properties, payment of taxes, and conditions to defeasance.
• · New Fifth Third 4.000% Senior Notes due 2029 mature February 1, 2029, and are redeemable on or after November 3, 2028 at 100% of principal plus accrued interest.
• · New Fifth Third 5.982% Fixed-to-Floating Rate Senior Notes due 2030 mature January 30, 2030; interest is fixed at 5.982% until January 30, 2029, then floats at Compounded SOFR plus 2.155%.
• · The New Fifth Third Notes are unregistered and may only be offered under exemptions from registration.
• · Fifth Third entered into a Registration Rights Agreement with J.P. Morgan Securities LLC, agreeing to file a registration statement within 365 days of the Final Settlement Date.
• · If Fifth Third fails to comply with registration obligations, it must pay additional interest on the New Fifth Third Notes.

10-06-2026

This DEFA14A filing is an additional proxy statement submitted by Enovix Corp to the SEC on June 10, 2026. It contains forward-looking statements and references to quarterly reports on Form 10-Q, without providing any specific financial results or comparative performance data.

10-06-2026

Classover Holdings, Inc., now named KIDZ AI Inc., filed a Current Report (8-K) on June 10, 2026, addressing amendments to its charter/bylaws and other corporate governance matters. The company had previously changed its name from Classover Holdings to KIDZ AI Inc. on May 29, 2026. The filing covers items 3.03, 5.03, 5.07, and 9.01; however, specific financial figures and detailed terms of the amendments were not provided in this summary-level view.

• · The filing includes items 3.03 (Material Modification to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws), 5.07 (Submission of Matters to a Vote of Security Holders), and 9.01 (Financial Statements and Exhibits).
• · The company's CIK is 0002022308, and it is incorporated in Delaware with a fiscal year ending December 31.
• · Prior to this filing, the company changed its name from Classover Holdings, Inc. to KIDZ AI Inc. as of May 29, 2026.
• · The filing date of the 8-K is June 10, 2026.

10-06-2026

Visium Technologies, Inc. terminated its Amended and Restated Letter of Intent to acquire ConnexUS AI Inc., after the Board determined the ConnexUS incubation had failed. The mutual release extinguishes all payment obligations, confirms ConnexUS retains full ownership of the ATHENA platform IP, and includes the resignation of Cheddi Rai from all officer and director positions at Visium. The Board now consists of Paul R. Taylor (Chairman & CEO), Mark Lucky (CFO), and David Pierce (Independent Director).

• · The LOI termination is effective as of June 9, 2026.
• · Visium has returned or destroyed all copies of ATHENA IP in its possession.
• · ConnexUS waived all payment obligations including Committed Contract Value, Minimum Monthly Fees, Pass-Through Costs, interest, liquidated damages, and collection costs.
• · The mutual release covers claims for breach of contract, breach of fiduciary duty, fraud, misrepresentation, unjust enrichment, quantum meruit, tortious interference, and securities law claims.
• · The agreement includes confidentiality and non-disparagement obligations.
• · Disputes will be resolved by binding arbitration in Broward County, Florida under the Revised Florida Arbitration Code.

10-06-2026

Bark, Inc. filed its 10-K for the fiscal year ended March 31, 2026, reporting total revenue of $394.8M, down 18.5% from $484.2M in FY2025, driven by a 21.9% decline in Direct-to-Consumer (DTC) revenue to $324.9M. The company narrowed its net loss to $39.0M from $32.9M in the prior year, a 18.6% increase in net loss, while gross margin improved to 61.3% from 62.4%. Total orders fell 23.8% to 10.06 million from 13.21 million, though average order value remained nearly flat at $31.06.

• · DTC gross margin improved to 68.4% in FY2026 from 66.1% in FY2025.
• · Commerce gross profit declined 9.7% YoY to $28.1M.
• · Shipping and fulfillment expense decreased 14.1% YoY to $119.4M.
• · Advertising and marketing as a percentage of revenue fell to 15.0% from 17.3%.
• · General and administrative expense as a percentage of revenue increased to 56.4% from 52.3%.
• · Interest income dropped 61.8% YoY to $1.9M.
• · Interest expense decreased 33.4% YoY to $1.9M.
• · Other income, net surged 768.2% YoY to $1.1M.
• · Commerce revenue grew 2.3% YoY, partially offsetting DTC decline.
• · Total orders fell 23.8% YoY, while average order value remained essentially flat at $31.06.

10-06-2026

Fervo Energy (Nasdaq: FRVO) announced the promotion of Sarah Jewett to Chief Operating Officer (COO), effective June 10, 2026. Jewett, who joined the company in 2020 and previously led the strategy department, will oversee centralized corporate operations as the company accelerates its standardized geothermal development model. The filing highlights the company's growing project pipeline across utility offtake, AI hyperscaler demand, and industrial power applications, but provides no financial metrics or period-over-period comparisons.

• · Sarah Jewett spent her twenties running hydraulic fracturing crews for Schlumberger across the Permian, North Slope, and Western U.S. basins.
• · She holds an M.B.A. from Harvard Business School and a Bachelor of Engineering in Mechanical Engineering from Dartmouth College.
• · Jewett joined Fervo in 2020 to lead the strategy department after working at Select Energy Services.
• · The COO role is newly created to centralize supply chain, land, permitting, policy, and people functions as the company scales.

10-06-2026

Slide Insurance Holdings, Inc. held its Annual Meeting of Stockholders on June 10, 2026, where shareholders elected three Class I directors (Robert Gries, Andrew Wright, and Beth W. Bruce) and ratified the selection of Forvis Mazars, LLP as the independent auditor for fiscal year 2026. All proposals passed with strong shareholder support, though director Andrew Wright received a notable 9,990,367 withheld votes (11.96% of votes cast), indicating some shareholder dissent.

• · Total votes for Proposal 1: Robert Gries received 80,945,212 votes for, 2,549,557 withheld; Andrew Wright received 73,504,402 for, 9,990,367 withheld; Beth W. Bruce received 74,191,861 for, 9,302,908 withheld.
• · Broker non-votes for all director nominees were 11,727,479.
• · Proposal 2 (auditor ratification) passed with 93,541,941 votes for, 12,985 against, and 1,667,322 abstentions.
• · The annual meeting was held on June 10, 2026, and the filing was made the same day.

10-06-2026

Barinthus Biotherapeutics plc filed a DEF 14A proxy statement for its Annual General Meeting to be held on July 2, 2026. The Board recommends voting FOR all seven proposals, including re-election of directors Karen T. Dawes and Anne M. Phillips, re-appointment of PricewaterhouseCoopers LLP as auditors, and approval of the directors' compensation report. The record date for ordinary shareholders is June 30, 2026, and for ADS holders is June 10, 2026.

• · Meeting date: July 2, 2026
• · Record date for ordinary shareholders: June 30, 2026 (6:30 p.m. London Time)
• · Record date for ADS holders: June 10, 2026 (5:00 p.m. Eastern Time)
• · Quorum requirement: at least 33 1/3% of issued shares entitled to vote
• · Proxies for ordinary shareholders must be received by 2:30 p.m. London Time on June 30, 2026
• · ADS voting deadline: 12:00 p.m. Eastern Time on June 26, 2026
• · Board recommends FOR all seven proposals

10-06-2026

BancFirst Corporation announced the acquisition of SpiritBank, a privately held community bank in Tulsa, Oklahoma, on June 10, 2026. The acquisition adds approximately $939.6 million in total assets, $618.4 million in loans, and $847.2 million in deposits. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, and Spirit will operate under its present name until merged into BancFirst.

• · The filing was made under Item 7.01 Regulation FD Disclosure.
• · SpiritBank is headquartered in Tulsa, Oklahoma.
• · Spirit will retain its name until merged into BancFirst.
• · The closing is in Q4 2026.

10-06-2026

Iovance Biotherapeutics held its Annual Meeting on June 10, 2026, with 74% of shares represented. All seven proposals were approved, including the election of directors, executive compensation (non-binding), ratification of Ernst & Young as auditor, an increase in authorized shares from 500M to 650M, and an amendment to the ESPP. Additionally, on June 4, 2026, the company received marketing authorization from Australia's TGA for Amtagvi® for advanced melanoma.

• · Proposal 1: All director nominees elected with votes ranging from 181M to 186M for.
• · Proposal 2: Executive compensation approved with 160.5M for, 36.1M against, 2.7M abstain, 130.2M broker non-votes.
• · Proposal 3: Frequency of say-on-pay votes set at 1 year with 188.1M votes.
• · Proposal 4: Ratification of Ernst & Young approved with 317.7M for, 6.4M against, 5.4M abstain.
• · Proposal 5: ESPP amendment approved with 178.7M for, 19.0M against, 1.7M abstain, 130.2M broker non-votes.
• · Proposal 6: Authorized share increase approved with 255.0M for, 71.4M against, 3.1M abstain.
• · Proposal 7: Adjournment proposal approved with 267.9M for, 56.4M against, 5.3M abstain.
• · Marketing authorization from Australia TGA for Amtagvi® received on June 4, 2026.

10-06-2026

Valaris Limited held its 2026 Annual General Meeting on June 10, 2026, with 88.24% of eligible shares represented. All director nominees were elected, and shareholders approved executive compensation on an advisory basis and ratified KPMG LLP as the independent auditor. However, director Kristian Johansen received the lowest support with 53,195,742 votes for and 3,912,582 against, indicating notable shareholder dissent.

• · Director Kristian Johansen received the highest number of votes against (3,912,582) among all nominees.
• · Director Catherine J. Hughes also faced significant opposition with 2,622,087 votes against.
• · The advisory vote on executive compensation had 928,586 votes against and 447,037 abstentions.
• · KPMG LLP's appointment as auditor was approved with 57,705,016 votes for, 3,378,791 against, and 28,186 abstentions.
• · There were 3,987,572 broker non-votes for all director elections and the executive compensation proposal.

10-06-2026

Varagon Capital Corporation held its 2026 annual meeting on June 9, 2026, where shareholders elected James Gertie as a Class I director with overwhelming support (30,503,999 votes for vs. 63,545 withheld). The meeting had a quorum of 30,567,544 shares out of 41,536,907 outstanding shares. No other proposals were voted on, and no financial results or performance metrics were disclosed.

• · The company is an emerging growth company as defined under SEC rules.
• · The record date for the annual meeting was April 15, 2026.
• · The director elected will serve until the 2029 annual meeting or until a successor is qualified.
• · No other proposals were voted on at the meeting.

10-06-2026

Evernorth Holdings Inc. filed a Form 425 on June 10, 2026, regarding its proposed business combination with Armada Acquisition Corp. II (SPAC) and Pathfinder Digital Assets LLC. The transaction involves a merger where Evernorth will become the public entity, with plans to build an institutional XRP treasury and execute DeFi yield strategies. The filing includes forward-looking statements and risk factors, but no specific financial figures or performance metrics are disclosed.

• · Business Combination Agreement dated October 19, 2025
• · Registration Statement filed on March 18, 2026
• · Private Placement Transactions are part of the Proposed Transactions
• · Securities to be issued have not been registered under the Securities Act
• · Risk factors include volatility of XRP price, redemptions, and regulatory changes